Get Thin MD Review

The verdict: a low-cost flat-rate option built around a 3-month commitment

Get Thin MD (legally Get Thin MD LLC) is a nationwide, fully async telehealth service whose entire pitch is summed up by its tagline: "same price, every dose, no hidden fees." That price-lock promise is the real reason to look here. Unlike the many platforms that quietly raise your bill as you titrate up to higher GLP-1 doses, Get Thin MD says your monthly cost stays put no matter what dose you land on. If you want predictable, low-cost compounded semaglutide and you're comfortable paying for a few months up front, this is one of the cheaper ongoing options in the category. If you want a brand-name GLP-1 covered by insurance or a high-touch clinical relationship, look elsewhere.

How the pricing actually works — and where the cheap number comes from

Get Thin MD uses a flat, dose-independent model. The standard rate for compounded semaglutide is $169 per month on the 3-month plan, or a bit more if you pay month to month rather than committing to the quarter. The much-advertised $119 figure is a first-month "Spring Sale" discount tied specifically to the 3-month plan — it's a teaser, not the standing rate, so budget around $169 as your real ongoing cost. For context, the category median for ongoing compounded pricing sits around $169, so Get Thin MD lands right at or just below the middle of the pack rather than being a dramatic outlier. The flat-dose structure is the genuinely patient-friendly part: many people find their per-month cost balloons elsewhere once they reach maintenance doses, and that doesn't happen here.

• Compounded semaglutide: $169/mo on the 3-month plan (slightly higher month-to-month)
• Spring Sale intro: as low as $119 for the first month on the 3-month plan
• Compounded tirzepatide is also offered at a higher flat monthly rate
• Price-lock promise: "your price will never increase, no matter what dose you're on"

What your monthly fee covers

The flat price is genuinely all-in. Get Thin MD says each monthly payment covers the prescription medication itself, a licensed provider's review of your intake, a personalized treatment plan, ongoing care coaching, and free expedited shipping. There are no office visits and no insurance to wrangle — the whole evaluation happens asynchronously through an online questionnaire. That bundling is part of why the headline number is easy to compare against rivals that add separate consult or shipping fees.

The medications: compounded first, brand-name available

The core catalog is injectable compounded semaglutide and injectable compounded tirzepatide. For patients who want or need the FDA-approved versions, Get Thin MD also says it can prescribe brand-name Ozempic and Zepbound "where appropriate." That dual menu is a real convenience — you can start on a lower-cost compounded formula and have a path to brand-name drugs on the same platform. Worth being clear-eyed, though: the compounded products are the headliners and the affordable ones, while the brand-name route depends on medical appropriateness and won't carry these flat prices.

What genuinely sets it apart — and the catch underneath it

Two things make Get Thin MD distinct. First is that flat, dose-locked pricing, which removes the most common nasty surprise in GLP-1 telehealth. Second is the breadth of its menu: this isn't a weight-loss-only shop. The same platform sells sermorelin injections, NAD+, HRT/estradiol, and hair-loss products, so someone running multiple wellness protocols can consolidate them in one place. The flip side of that breadth is that it's a wide funnel — expect to be offered add-on protocols that have nothing to do with weight loss, and stay focused on what you actually came for.

Trust, safety and what we couldn't verify

We live-verified Get Thin MD by navigating the real site (getthinusa.com), and the confidence here is moderate rather than high — for honest reasons. To its credit, the company publishes the required FDA disclaimer that "the FDA does not review or approve any compounded medications for safety or effectiveness," and we found no FDA warning letters on file for the business. But the platform does not name its compounding pharmacy partners, so there's no way for an outsider to confirm the source of the drug or whether batches are independently tested — a real transparency gap for compounded medicines. It also markets itself as "available nationwide" without publishing an actual state-by-state list, so confirm your state is served at intake.

• Publishes the FDA compounded-medication disclaimer and shows no FDA warning letters
• Compounded drugs are not FDA-approved and lack the review brand-name GLP-1s receive
• Pharmacy partners are not disclosed — compounding source and batch testing can't be verified
• "Nationwide" is claimed but no state list is published — verify coverage before paying
• The "9.6 lbs in 30 days" figure comes from self-reported patient data, not a clinical trial

Who should choose it — and who should skip it

Choose Get Thin MD if you want low-cost compounded semaglutide with a price that won't climb as your dose does, you're fine committing to a 3-month plan to get the best rate, and you value the convenience of a no-insurance, no-visit process plus an optional broader wellness menu. Skip it if you specifically want an insurance-billed brand-name prescription, if you need a named, verifiable pharmacy and detailed batch documentation before you'll inject a compounded product, or if you prefer a provider that lists exactly which states it operates in up front.

Bottom line

Get Thin MD is a solid budget-tier pick for compounded GLP-1 treatment, and its dose-locked flat pricing is a meaningfully patient-friendly feature in a category full of creeping bills. The trade-off is transparency: undisclosed pharmacy partners and a vague nationwide claim mean you're trusting the brand more than the paper trail. Go in knowing the real ongoing cost is around $169 rather than the $119 teaser, confirm your state and the medication source at intake, and read our scoring methodology to see how we weigh price against verification.